Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Small Cell Lung Carcinoma 63Leukemia, Myeloid, Acute 14Carcinoma, Non-Small-Cell Lung 14Lung Neoplasms 11Lymphoma, Non-Hodgkin 9Lymphoma, Large B-Cell, Diffuse 9Recurrence 8Neoplasms 8Parkinson Disease 4, Autosomal Dominant Lewy Body 6Lymphoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Carcinoma, Small Cell 4Ovarian Neoplasms 3Leukemia 3Hodgkin Disease 3Extensive Stage Small Cell Lung Cancer 3Small Cell Lung Cancer Extensive Stage 2SCLC 2Osteosarcoma 2Neoplasm Metastasis 2Lymphoma, B-Cell 2Lymphatic Diseases 2Immunoproliferative Disorders 2Hematologic Diseases 2Glioblastoma 2Ependymoma 2Advanced Solid Tumors 2Widespread Small Cell Lung Cancer 1Unresectable Locally Advanced or Metastatic Solid Tumors 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

atezolizumab 2Etoposide 2Carboplatin 2tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Small Cell Lung Cancer Extensive Stage × Etoposide × Clear all
NCT07227597 2026-05-28

MK-6070-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
170 enrolled
Thoracic

Small Cell Lung Cancer Extensive Stage

NCT06030258 2025-04-30

IN10018 Combination Therapy in Treatment-naïve ES-SCLC

InxMed (Shanghai) Co., Ltd.

Phase 1/2 Recruiting
120 enrolled
Thoracic

Small Cell Lung Cancer Extensive Stage

Data powered by HemOnc (CC BY 4.0) Colophon âš¡